MoonLake Immunotherapeuti...

NASDAQ: MLTX · Real-Time Price · USD
54.42
-0.46 (-0.84%)
At close: Aug 15, 2025, 3:59 PM
54.39
-0.06%
After-hours: Aug 15, 2025, 04:20 PM EDT

MoonLake Immunotherapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 101.85K n/a n/a n/a 19.74K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
742K 378K 50.92K 32.52K 28.11K 22.81K 3.29K 3.29K 3.29K 3.29K n/a 3.29K n/a n/a n/a n/a n/a n/a
Gross Profit
-742K -378K 50.92K -32.52K -28.11K -22.81K 16.45K -3.29K -3.29K -3.29K n/a -3.29K n/a n/a n/a n/a n/a n/a
Operating Income
-60.7M -47.48M -49.58M -43.11M -30.58M -19.82M -15.03M -12.98M -13.19M -12.93M -16.7M -14.77M -17.65M -15.94M -2.22M -6.27M -32.68M -94.11K
Interest Income
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 17.82K
Pretax Income
-55.96M -40.41M -46.35M -36.02M -24.68M -13.91M -7.84M -11.59M -12.34M -12.21M -16.46M -14.73M -17.41M -15.87M -2.22M -6.29M -32.69M -76.29K
Net Income
-55.22M -40.25M -45.6M -35.39M -24.27M -13.67M -7.44M -9.43M -10.14M -12.22M -1.94M -14.74M -17.42M -15.88M -2.22M -6.29M -32.69M -76.29K
Selling & General & Admin
10.94M 11.03M 9.22M 7.38M 6.92M 6.81M 6.93M 5.39M 4.48M 5.52M 5.33M 5.75M 6.25M 5.49M 2.22M 5.6M 2.81M 94.11K
Research & Development
49.02M 36.46M 40.36M 35.74M 23.63M 12.99M 8.09M 7.59M 8.7M 7.42M 11.37M 9.02M 11.4M 10.45M 12.1M 669.53K 29.87M n/a
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 37.59K n/a 69.51K 6.8K -20.84K -3.78K n/a
Operating Expenses
59.96M 47.48M 49.58M 43.11M 30.55M 19.8M 15.03M 12.98M 13.19M 12.93M 16.7M 14.77M 17.65M 15.94M 2.22M 6.27M 32.68M 94.11K
Interest Expense
2.04M -18K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -10.67M n/a n/a n/a
Cost & Expenses
60.7M 47.48M -49.58M 43.11M 30.58M 19.82M 15.03M 12.98M 13.19M 12.93M 16.7M 14.77M 17.65M 15.94M 2.22M 6.27M 32.68M 94.11K
Income Tax Expense
95K -153K 41.14K 92.11K 78.7K 70.25K 44.31K 28.92K 10.15K 11.01K 11.01K 8.74K 9.28K 7.33K 5.71K n/a -107 n/a
Shares Outstanding (Basic)
63.28M 63.23M 63.07M 62.9M 62.87M 62.64M 59.91M 53.52M 43.72M 39.06M 38.84M 36.93M 35.2M 36.93M 14.8M 36.93M 36.93M 14.8M
Shares Outstanding (Diluted)
63.28M 63.23M 63.07M 62.9M 62.87M 62.64M 59.91M 53.52M 43.72M 39.06M 38.84M 36.93M 35.2M 36.93M 14.8M 36.93M 36.93M 14.8M
EPS (Basic)
-0.87 -0.63 -0.72 -0.56 -0.39 -0.22 -0.12 -0.18 -0.23 -0.31 -0.05 -0.4 -0.49 -0.43 -0.15 -0.17 -0.89 -0.01
EPS (Diluted)
-0.87 -0.63 -0.72 -0.56 -0.39 -0.22 -0.12 -0.18 -0.23 -0.31 -0.05 -0.4 -0.49 -0.43 -0.15 -0.17 -0.89 -0.01
EBITDA
-53.18M -40.01M -45.05M -43.08M -30.55M -19.8M -15.03M -12.97M -13.18M -12.93M -16.69M -14.77M -17.65M -15.94M -2.22M -6.26M -32.68M n/a
EBIT
-53.92M -40.39M -46.35M -43.11M -30.58M -19.82M -15.03M -12.98M -13.19M -12.93M -16.7M -14.77M -17.65M -15.94M -2.22M -6.27M -32.68M -76.29K
Depreciation & Amortization
742K 378K 1.3M 32.52K 28.11K 22.81K 3.29K 3.29K 3.29K 3.29K 3.29K 3.29K 3.29K 2.49K 3.48K 2.27K 107.00 55.21K